In life sciences, AI architecture must account for compliance from the start, not retrofit to it later.

Medical device, diagnostics, biopharma, and the discovery bench run on different regulatory regimes and data types. We engineer systems that meet the governing rules and hold up under inspection.

01 · The shift

Experimental tools now touch regulated operations.

Regulators issue guidance for continuous learning, and payers demand software-generated evidence. Tools that started as R&D experiments now impact filings, inspections, and reimbursement. The challenge is deploying AI in regulated operations without creating compliance findings.

02 · Our stance

Independent architecture.

We resell no software and take no vendor commissions. Independence matters heavily in life sciences because platform choices carry long-term validation, audit, and switching costs. We match the architecture to the data and the regulatory posture, and the team that sets the strategy writes the code.

03 · Where it sits

Value sits in pipelines and compliance records.

Returns depend on locked data, compliance records, and disconnected pipelines across quality, manufacturing, clinical, and commercial operations. Some teams are standardizing records; others run an audit-ready layer and need scale. That groundwork dictates the AI layer's actual return.

Start here

See where AI belongs in a regulated operation

A short assessment maps the regulatory regime, the data, and the sequence before any build.

Request an assessment